Write in a clean editor, then format for Journal of Psoriasis and Psoriatic Arthritis in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Psoriasis and Psoriatic Arthritis is a peer-reviewed journal published by SAGE, covering Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments, Dermatology and Skin Diseases.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Journal of Psoriasis and Psoriatic Arthritis, 12(3), pp. 45–58.
Formats any DOI in Journal of Psoriasis and Psoriatic Arthritis style. No sign-up. |
| Publishes research in | Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Dermatology and Skin Diseases Health Systems, Economic Evaluations, Quality of Life Rheumatoid Arthritis Research and Therapies |
| ISSN | 2475-5303 |
| Citation impact (2-yr) | 1.63 |
| h-index | 17 |
| i10-index | 31 |
| Total citations | 1,135 |
| Top institutions publishing here | Icahn School of Medicine at Mount Sinai |
| Journal website | www.psoriasis.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Tumor necrosis factor a (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients' quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the…
BACKGROUND: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including clinical features associated with the development of arthritis among children with psoriasis and subsequent risk of inflammatory comorbidities. OBJECTIVE: To identify the overall risk of arthritis among children with psoriasis and subsequent risk of inflammatory comorbidities. METHODS: Using Clinformatics™ DataMart (OptumInsight,…
Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to…
The management of psoriatic disease in human immunodeficiency virus (HIV)-positive patients is challenging. Psoriasis in HIV-positive patients is often severe, progressive, and resistant to first- and second-line therapies, including topical treatments, phototherapy, highly active antiretroviral therapy (HAART), and oral retinoids. Other systemic agents used to treat psoriasis, such as methotrexate and cyclosporine, are immunosuppressants and…
Background: Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by sterile pustules, erythema, and scaling on the palms or soles of the feet. Apremilast is a systemic agent that inhibits phosphodiesterase 4 and is approved for the treatment of plaque psoriasis and psoriatic arthritis. Objective: To demonstrate the safety and efficacy of apremilast…
